More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$628148832
EPS
-0.61
P/E ratio
--
Price to sales
115.64
Dividend yield
--
Beta
-0.842955
Previous close
$10.27
Today's open
$10.20
Day's range
$9.79 - $10.22
52 week range
$8.63 - $26.19
show more
CEO
Daniel Tass
Employees
125
Headquarters
Chtillon,
Exchange
NASDAQ Capital Market
Shares outstanding
62877761
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
DBV Technologies NASDAQ: DBVT is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, executives said at Guggenheim's Healthcare Innovation Conference.
MarketBeat • Nov 9, 2026

DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds
DBV Technologies is rated Speculative Strong Buy with a $42 per ADS fair value, despite recent sector- and company-specific share price declines. My revised DCF incorporates higher discount rates, regulatory delay probabilities, and dilution but still indicates attractive risk/reward at approximately $10 per ADS. Key risks include regulatory delays, manufacturing issues at Fareva Amboise, and management credibility concerns, with a total investment loss remaining possible.
Seeking Alpha • Nov 7, 2026

DBV Technologies to Participate in Upcoming November Investor Conferences
Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in November: Guggenheim Securities 3rd Annual Healthcare Innovation Conference – November 9, 2026 Format: Fireside ChatTime: 8:00 am ETLocation: Boston, MA 2026 LifeSci Growth & Innovation Summit – November 16, 2026 Format: 1 on 1 MeetingsLocation: London, UK A live webcast of the fireside chat will be available on the Events section of the Company's website here. Replays will also be available on DBV Technologies' website for 90 days after the event.
GlobeNewsWire • Nov 2, 2026

What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contract manufacturing partner.
MarketBeat • Oct 29, 2026

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness towards the launch of the VIASKIN® Peanut Patch in children aged 4-7 years in the US, if approved Reported cash and cash equivalents of $165.7 million as of September 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, October 28, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage specialty biopharmaceutical company, today reported financial results for the Third Quarter of 2026. The quarterly and nine months financial statements were approved by the Board of Directors on October 28, 2026.
GlobeNewsWire • Oct 28, 2026

DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Wednesday, October 28th, at 5:00 p.m. ET to review its third quarter 2026 financial results and provide a business update.
GlobeNewsWire • Oct 27, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. DBV has requested Priority Review of the BLA.
GlobeNewsWire • Sep 29, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences
Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format: Fireside Chat Time: 1:00pm ETLocation: New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format: 1 on 1 MeetingsLocation: New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format: Fireside ChatTime: 3:00pm ETLocation: New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.
GlobeNewsWire • Sep 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
GlobeNewsWire • Sep 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell DBV Technologies S.A. commission-free¹. Build wealth for the long term using automated trading and transfers.